Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Prevention

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

Cancer Prevention

Cancer Prevention

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Preventive Healthcare Services

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.

Future oncology (London, England)·2026

Same author

Cancer Genetic Risk Assessment (CGRA) Certification: Outcomes from the First Six Years.

European journal of breast health·2026

Same author

Prenatal Cell-Free DNA Screening With Fetal Fraction Amplification at 6-9 Weeks of Gestation.

Obstetrics and gynecology·2026

Same author

Results of breast cancer risk assessment and hereditary cancer genetic testing in community obstetrics and gynaecology practice following a prospective quality Improvement initiative.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2026

Same author

Optimizing Hereditary Cancer Risk Assessment and Genetic Testing Workflow in Interprofessional Women's Health Practice: A Multicenter Survey of Advanced Practice Providers.

Journal of midwifery & women's health·2026

Same author

Outcomes and Management of Pregnancies Screening Positive for Microdeletions 22q11.2, 15q11.2, 1p36, 4p, or 5p: A Retrospective Cohort Study.

The application of clinical genetics·2026

Search research articles

Related Experiment Video

Updated: Apr 10, 2026

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

Cancer Risk Assessment and Hereditary Cancer Genetic Testing in a Community OBGYN Setting.

Edith Smith¹, Logan Schneider¹, Lauren Lenz¹

¹Myriad Genetics, Utah, USA.

European Journal of Breast Health

|April 9, 2026

Summary

This summary is machine-generated.

Updated guidelines show over 28% of individuals meet criteria for hereditary cancer genetic testing, a significant increase. Additionally, 36.5% of patients face elevated breast cancer risk, necessitating management changes.

Keywords:

Risk assessment community setting hereditary cancer

More Related Videos

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Apr 10, 2026

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

Oncology
Genetics
Preventive Medicine

Background:

National guidelines recommend cancer risk assessment and hereditary cancer genetic testing for eligible individuals.
Previous estimates indicated about 24% of unaffected individuals met criteria for hereditary cancer testing.
Recent guideline expansions and improved understanding necessitate updated assessments.

Purpose of the Study:

Determine the percentage of unaffected patients meeting updated genetic testing criteria.
Outline breast cancer risk assessment and genetic test results.
Delineate the percentage of patients recommended for management changes.

Main Methods:

A process-intervention study was conducted across 5 OBGYN practices from September 2021 to November 2022.
Hereditary cancer risk assessment and germline genetic testing (MyRisk panel) were implemented.
Breast cancer risk was stratified using the Tyrer-Cuzick model and RiskScore.

Main Results:

Over 28% of individuals met National Comprehensive Cancer Network (NCCN) testing criteria.
Among those tested, 3.2% had pathogenic variants identified.
36.5% of patients exhibited a lifetime breast cancer risk of 20% or higher.

Conclusions:

Over 28% of individuals meet current genetic testing guidelines, exceeding previous estimates.
A significant portion of patients (36.5%) require medical management changes due to elevated breast cancer risk.
Comprehensive risk assessment is crucial for tailoring patient management to individual risk levels.